Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 7/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.49 |
| ▸ | KRAS | P01116 | 14/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29321765 | 1.00 | MAPK3 (0.49) | MAPK3MAPK1KRASRAF1 | |
| SCHEMBL29321757 | 0.98 | MAPK3 (0.47) | MAPK3MAPK1KRASRAF1 | |
| SCHEMBL29321761 | 0.94 | MAPK3 (0.43) | MAPK3MAPK1KRASRAF1 | |
| SCHEMBL30978049 | 0.94 | MAPK3 (0.43) | MAPK3MAPK1KRASRAF1 | |
| SCHEMBL30850173 | 0.94 | MAPK3 (0.50) | MAPK3MAPK1KRASRAF1 | |
| SCHEMBL29321751 | 0.92 | MAPK3 (0.40) | MAPK3MAPK1KRASRAF1 | |
| SCHEMBL31527172 | 0.88 | MAPK3 (0.42) | MAPK3MAPK1KRASRAF1 | |
| SCHEMBL30850176 | 0.88 | MAPK3 (0.43) | MAPK3MAPK1KRASRAF1 | |
| SCHEMBL31382523 | 0.84 | KRAS (0.54) | MAPK3MAPK1KRASRAF1 | |
| SCHEMBL29322121 | 0.83 | KRAS (0.50) | MAPK3MAPK1KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137699-A1 | OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137699-A1 | OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | SCN1B, OXER1, NR3C2 | MAPK3 2657/4885MAPK1 2783/4885KRAS 1034/4885 |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | AZI2, HDAC5, HDAC4 | MAPK3 3866/4885MAPK1 4628/4885KRAS 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.